期刊文献+

儿科患者使用奥司他韦的临床应用分析 被引量:4

Clinical Application of Oseltamivir to Pediatric Patients
下载PDF
导出
摘要 目的了解肇庆市第二人民医院儿科患者应用奥司他韦的情况,评价其用药合理性,促进临床合理用药。方法采用回顾性调查方法,抽查我院普儿科2016年01月—2016年06月应用奥司他韦的病历,共226例,调查用药情况。结果本品以经验性用药为主,用法皆为每天2次,疗程以1~5天多见(189例,83.63%)。用量合理有81例(占35.84%),用量偏小136例(占60.18%)。本品单独应用仅4例,与抗病毒药联用73例次(28.73%),与抗菌药物联用22例次(8.67%),三者联用159例次(62.60%)。联用方案以联合喜炎平注射液(17.32%)最多。结论奥司他韦用药情况基本合理,但在剂量、疗程与联合用药方面存在不合理现象,需在这几方面加强用药监控。 Objective To analyze the use of oseltamivir in treatment of pediatric patients in Zhaoqing No. 2 Peopler s Hospital (referred to as our hospital) and evaluate its rationality so as to promote the properly clinical use of drugs. Meth-ods A retrospective method was conducted to investigate the oseltamivir use among 226 pediatric patients in our hospital from January 2016 to June 2016. Results Oseltamivir was empirically administered twice a day with mostly course of treat-ment ≤five days (189 cases, 83. 63% ) ; 81 cases used reasonable daily dosage (3 5 . 84% ) and 136 cases did under the dosage (60. 18% ) . 4 cases took Oseltamivir single, 73 case/time took it in combination with antiviral drugs (28. 73% ) and 22 in combination with antibacterials (8. 67% ) and 159 in combination with the mentioned three drugs (62. 60% ). Xiyan- ping injection was the most common one in the combination (17. 32% ). Conclusion The use of Oseltamivir is generally reasonable, but there are some irrational uses in view of the dosage, course of treatment and combination with other drugs. It is necessary to strengthen the drug monitoring in the three aspects.
出处 《现代医院》 2017年第7期1057-1059,共3页 Modern Hospitals
关键词 儿童 奥司他韦 合理用药 调查 Children Oseltamivir Rational Use of Drugs Investigation
  • 相关文献

参考文献9

二级参考文献69

  • 1李家泰.临床毒理学与药物评价[J].中国临床药理学杂志,1994,10(3):184-188. 被引量:37
  • 2卫生部2009年《甲型H1N1流感诊疗方案》.第3版,2009,2-13.
  • 3毕殿洲.药剂学[M].1版.北京:中国医药科技出版社,2004:167.
  • 4吴永佩 主编.药学综合知识与技能[M].北京:中国医药科技出版社,2000.85-105.
  • 5U.S.Food and Drug Administration.Tamiflu(oseltamivir)[EB/OL].[2013-05-08].http://www.fda.gov/.../AdvisoryCommittees/CommitteesMeetingMaterials/PediatricAdvisoryCommittee/UCM302450.pdf.
  • 6U.S.Food and Drug Administration.FDA expands Tamiflu’s use to treat children younger than 1 year[EB/OL].[2013-05-08].http://www.fda.gov/NewsEvents/Newsroom/Press Announcements/ucm333205.htm.
  • 7Yu H,Feng Z,Uyeki TM,et al.Risk factors for severe illness with 2009 pandemic influenza A(H1N1)virus infection in China[J].Clin Infect Dis,2011,52(4):457.
  • 8U.S.Centers for Disease Control and Prevention.Influenza antiviral medications:summary for clinicians[EB/OL].[2013-05-08].http://www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm.
  • 9U.S.Food and Drug Administration.Review of post-market reports in the adverse event reporting system(AERS)database associated with oseltamivir use in pediatric(0 to16 years)patients[EB/OL].[2013-05-08].http://www.fda.gov/.../AdvisoryCommittees/CommitteesMeetingMaterials/PediatricAdvisoryCommittee/UCM303007.pdf.
  • 10Hama R,Jones M,Okushima H,et al.Oseltamivir and early deterioration leading to death:a proportional mortality study for 2009A/H1N1 influenza[J].Int J Risk Saf Med,2011,23(4):201.

共引文献377

同被引文献52

引证文献4

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部